Re: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal

in response to

Re: German drug maker Morphosys to buy Constellation Pharma in $1.7 billion deal

KayakerBC

posted on Jun 04, 2021 10:12AM

Bear says..." However, in my opinion Zenith has a much more advanced program and is worth more."

KBC says... " but anyhow, here we sit at 30 cents."

I say...just keep loading up and hope for the best. That's what I'm doing. Zenith may break out sooner than RVX.